Indiana 2025 Regular Session

Indiana Senate Bill SB0514 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2	Introduced Version
3	3	SENATE BILL No. 514
4	4	_____
5	5	DIGEST OF INTRODUCED BILL
6	6	Citations Affected: IC 27-8-40; IC 27-13-7-29.
7	7	Synopsis: Chimeric antigen receptor T-cell therapy. Provides that a
8	8	policy of accident and sickness insurance or health maintenance
9	9	organization contract that provides coverage for chimeric antigen
10	10	receptor (CAR) T-cell therapy may not refuse to contract or deny
11	11	coverage for the administration of any CAR T-cell therapy by any
12	12	provider that qualifies as a certified health care facility by the federal
13	13	Food and Drug Administration for the applicable CAR T-cell therapy.
14	14	Effective: July 1, 2025.
15	15	Leising
16	16	January 16, 2025, read first time and referred to Committee on Health and Provider
17	17	Services.
18	18	2025 IN 514—LS 7414/DI 141 Introduced
19	19	First Regular Session of the 124th General Assembly (2025)
20	20	PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana
21	21	Constitution) is being amended, the text of the existing provision will appear in this style type,
22	22	additions will appear in this style type, and deletions will appear in this style type.
23	23	Additions: Whenever a new statutory provision is being enacted (or a new constitutional
24	24	provision adopted), the text of the new provision will appear in this style type. Also, the
25	25	word NEW will appear in that style type in the introductory clause of each SECTION that adds
26	26	a new provision to the Indiana Code or the Indiana Constitution.
27	27	Conflict reconciliation: Text in a statute in this style type or this style type reconciles conflicts
28	28	between statutes enacted by the 2024 Regular Session of the General Assembly.
29	29	SENATE BILL No. 514
30	30	A BILL FOR AN ACT to amend the Indiana Code concerning
31	31	insurance.
32	32	Be it enacted by the General Assembly of the State of Indiana:
33	33	1 SECTION 1. IC 27-8-40 IS ADDED TO THE INDIANA CODE AS
34	34	2 A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE JULY
35	35	3 1, 2025]:
36	36	4 Chapter 40. Coverage for Chimeric Antigen Receptor T-Cell
37	37	5 Therapy
38	38	6 Sec. 1. As used in this chapter, "chimeric antigen receptor T-cell
39	39	7 therapy" or "CAR T-cell therapy" means a treatment that is
40	40	8 designed to manipulate T-cell protein to recognize an antigen on
41	41	9 targeted tumor cells in an effort to eliminate cancer.
42	42	10 Sec. 2. As used in this chapter, "policy of accident and sickness
43	43	11 insurance" has the meaning set forth in IC 27-8-5-1. The term does
44	44	12 not include a policy, plan, or coverage set forth in IC 27-8-5-2.5(a).
45	45	13 Sec. 3. (a) This section applies to a policy of accident and
46	46	14 sickness insurance that is delivered, issued, or renewed after
47	47	15 December 31, 2025.
48	48	16 (b) A policy of accident and sickness insurance that provides
49	49	17 coverage for CAR T-cell therapy may not:
50	50	2025 IN 514—LS 7414/DI 141 2
51	51	1 (1) refuse to contract; or
52	52	2 (2) deny coverage;
53	53	3 for the administration of any CAR T-cell therapy by any provider
54	54	4 that qualifies as a certified health care facility in accordance with
55	55	5 the approved procedure under the CAR T-cell therapy product
56	56	6 license by the federal Food and Drug Administration for the
57	57	7 applicable CAR T-cell therapy.
58	58	8 SECTION 2. IC 27-13-7-29 IS ADDED TO THE INDIANA CODE
59	59	9 AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY
60	60	10 1, 2025]: Sec. 29. (a) This section applies to an individual contract
61	61	11 or a group contract that is entered into, amended, or renewed after
62	62	12 December 31, 2025.
63	63	13 (b) As used in this section, "chimeric antigen receptor T-cell
64	64	14 therapy" or "CAR T-cell therapy" means a treatment that is
65	65	15 designed to manipulate T-cell protein to recognize an antigen on
66	66	16 targeted tumor cells in an effort to eliminate cancer.
67	67	17 (c) An individual contract or a group contract that provides
68	68	18 coverage for CAR T-cell therapy may not:
69	69	19 (1) refuse to contract; or
70	70	20 (2) deny coverage;
71	71	21 for the administration of any CAR T-cell therapy by any provider
72	72	22 that qualifies as a certified health care facility in accordance with
73	73	23 the approved procedure under the CAR T-cell therapy product
74	74	24 license by the federal Food and Drug Administration for the
75	75	25 applicable CAR T-cell therapy.
76	76	2025 IN 514—LS 7414/DI 141